The patient underwent venous angiography at same hospital and proximal right subclavian vein stenosis was diagnosed. To treat the lesion, percutaneous intervention was performed and a 14 × 60 mm Zilver self-expandable nitinol endovascular stent (COOK, Bloomington, IN, USA) was deployed in the right

subclavian vein. Just after deployment of the stent, it migrated to the right ventricle. However, vital signs were stable and the patient was asymptomatic so another stent was successfully deployed by interventional radiologist. No further complications were reported and hemodialysis pressure of the outflow track improved. Therefore, no attempt Inhibitors,research,lifescience,medical was made to retrieve the migrated stent at the local hospital. One month later the patient experienced new onset of dysppnea on exertion and was transferred to our hospital. On physical examination, his heart sound was regular, and a grade II pansystolic murmur was audible Inhibitors,research,lifescience,medical along

both lower parasternal borders. There was no cardiomegaly upon chest X-ray but the right subclavian stent and another stent-like device was observed and located in the right side of the heart. A routine laboratory examination Inhibitors,research,lifescience,medical showed normal liver function test and mild anemia. Blood urea nitrogen and creatinine levels were 52 mg/dL and 10.0 mg/dL, respectively. Pro-brain natriuretic peptide concentration was 23,000 pg/dL. Transthoracic echocardiography showed 62% of left ventricular ejection fraction (EF) and trivial mitral regurgitation but the left ventricular Inhibitors,research,lifescience,medical enddiastolic dimension (LVEDD) was 59 mm and ratio of mitral E-velocity and E’ velocity (E/E’) was 12.4. Following examination of the right ventricle, a 4.55 × 1.72 cm coil-like structure with metallic echogenicity was observed. The migrated stent was seen at Inhibitors,research,lifescience,medical the right ventricular apex, and it spanned to the right atrium with significant tricuspid regurgitation (TR) flow on Doppler sonography (Fig. 1). Maximum velocity (Vmax) of TR

was 260 cm/s. Echocardiography one year prior had shown no significant TR. In addition EF was 70%, LVEDD was Edoxaban 55 mm and E/E’ was 8.7. Due to the risks of thrombosis, tricuspid valve injury, congestive heart failure, right ventricle perforation and cardiac arrhythmias, the patient was hospitalized and scheduled to undergo percutaneous intervention for stent removal. Fig. 1 A: Transthoracic echocardiography shows metallic coil-like structure in the right ventricle to right atrium through the tricuspid valve. B: Color Doppler image shows significant tricuspid regurgitation flow from the stent orifice. Fluoroscopy showed a metallic stent in the right ventricle (Fig. 2A) and another stent in the right subclavian vein through the Daporinad chemical structure superior vena cava. A vascular surgeon attended to remove the stent at the femoral vein level if it could not be removed through an 8 French sheath.